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Formulation and characterization of an apigenin-phospholipid phytosome (APLC)
for improved solubility, in vivo bioavailability, and antioxidant potential
Abstract
The apigenin-phospholipid phytosome (APLC) was developed to improve the aqueous solubility,
dissolution, in vivo bioavailability, and antioxidant activity of apigenin. The APLC synthesis was guided by
a full factorial design strategy, incorporating specific formulation and process variables to deliver an
optimized product. The design-optimized formulation was assayed for aqueous solubility, in vitro
dissolution, pharmacokinetics, and antioxidant activity. The pharmacological evaluation was carried out
by assessing its effects on carbon tetrachloride-induced elevation of liver function marker enzymes in a
rat model. The antioxidant activity was assessed by studying its effects on the liver antioxidant marker
enzymes. The developed model was validated using the design-optimized levels of formulation and
process variables. The physical-chemical characterization confirmed the formation of phytosomes. The
optimized formulation demonstrated over 36-fold higher aqueous solubility of apigenin, compared to that
of pure apigenin. The formulation also exhibited a significantly higher rate and extent of apigenin release
in dissolution studies. The pharmacokinetic analysis revealed a significant enhancement in the oral
bioavailability of apigenin from the prepared formulation, compared to pure apigenin. The liver function
tests indicated that the prepared phytosome showed a significantly improved restoration of all carbon
tetrachloride-elevated rat liver function marker enzymes. The prepared formulation also exhibited
antioxidant potential by significantly increasing the levels of glutathione, superoxide dismutase, catalase,
and decreasing the levels of lipid peroxidase. The study shows that phospholipid-based phytosome is a
promising and viable strategy for improving the delivery of apigenin and similar phytoconstituents with
low aqueous solubility.

Keywords
fsc2017

Disciplines
Pharmacy and Pharmaceutical Sciences

Comments
This is the authors' accepted manuscript version of the article. The final published article is available on
the publisher's webpage: http://doi.org/10.1016/j.ejps.2016.12.009

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 4.0
International License.

Authors
Darshan R. Telange, Arun T. Patin, Anil M. Pethe, Harshal Fegade, Sridhar Anand, and Vivek S. Dave

This article is available at Fisher Digital Publications: https://fisherpub.sjf.edu/pharmacy_facpub/117

*Manuscript

Formulation and characterization of an Apigenin-Phospholipid Phytosome (APLC) for
improved solubility, in vivo bioavailability, and antioxidant potential
Darshan R. Telange1, Arun T. Patil1, Anil M. Pethe2, Harshal Fegade1, Sridhar Anand3, Vivek S.
Dave3*
1

Department of Pharmaceutical Sciences, R.T.M. Nagpur University, Nagpur, Maharashtra, India

2

SPP School of Pharmacy & Technology Management, Pharmaceutics Division, SVKM's

NMIMS University, Mumbai, Maharashtra, India
3

St. John Fisher College, Wegmans School of Pharmacy, Rochester, NY, USA

*Corresponding author
Vivek S. Dave, Ph.D.
St. John Fisher College
Wegmans School of Pharmacy
Rochester, NY, 14534
Ph. 1-585-385-5297
Fax.1-585-385-5295
E-mail: vdave@sjfc.edu

Abstract
The apigenin-phospholipid phytosome (APLC) was developed to improve the aqueous solubility,
dissolution, in vivo bioavailability, and antioxidant activity of apigenin. The APLC synthesis was
guided by a full factorial design strategy, incorporating specific formulation and process
variables to deliver an optimized product. The design-optimized formulation was assayed for
aqueous solubility, in vitro dissolution, pharmacokinetics, and antioxidant activity. The
pharmacological evaluation was carried out by assessing its effects on carbon tetrachlorideinduced elevation of liver function marker enzymes in a rat model. The antioxidant activity was
assessed by studying its effects on the liver antioxidant marker enzymes. The developed model
was validated using the design-optimized levels of formulation and process variables. The
physical-chemical characterization confirmed the formation of Phytosomes. The optimized
formulation demonstrated over 36-fold higher aqueous solubility of apigenin, compared to that
of pure apigenin. The formulation also exhibited a significantly higher rate and extent of
apigenin release in dissolution studies. The pharmacokinetic analysis revealed a significant
enhancement in the oral bioavailability of apigenin from the prepared formulation, compared to
pure apigenin. The liver function tests indicated that the prepared phytosome showed a
significantly improved restoration of all carbon tetrachloride-elevated rat liver function marker
enzymes. The prepared formulation also exhibited antioxidant potential by significantly
increasing the levels of glutathione, superoxide dismutase, catalase, and decreasing the levels of
lipid peroxidase. The study shows that phospholipid-based phytosome is a promising and viable
strategy for improving the delivery of apigenin and similar phytoconstituents with low aqueous
solubility.

*Graphical Abstract

1. Introduction
Apigenin is a hydrophobic, polyphenolic flavonoid compound commonly found in fruits,
vegetables, tea, chamomile, wheat sprouts etc. (Shukla and Gupta, 2010). Apigenin-containing
preparations are marketed as dietary and herbal supplements (Peterson and Dwyer, 1998). It has
been demonstrated to possess anti-oxidant (Prince Vijeya Singh et al., 2004; Stanojević et al.,
2009), anti-microbial (Taleb-Contini et al., 2003), anti-inflammatory (Funakoshi-Tago et al.,
2011; Rithidech et al., 2012), anti-proliferative (Johnson and Gonzalez de Mejia, 2013), antiviral (Shibata et al., 2014), antidiabetic (Choi et al., 2014), and tumor inhibitory activities
(Choudhury et al., 2013; Ruela-de-Sousa et al., 2010).
The clinical potential of apigenin is stifled by its poor aqueous solubility, rapid metabolism,
and low oral bioavailability. Apigenin has an aqueous solubility of less than 2.16 µg/mL, and
rated as a Class II drug, based on the Biopharmaceutics Classification System (BCS) (Zhang et
al., 2012). After oral administration in rats, apigenin undergoes rapid metabolism to key
metabolites, such as p-hydroxy phenyl propionic acid, p-hydroxy cinnamic acid, and p-hydroxy
benzoic acid (Griffiths and Smith, 1972). Furthermore, it demonstrated only 51% bioavailability
after oral administration of Flos chrysanthemi extract (100 mg/kg) in rats (Chen et al., 2012).
Thus, it is necessary to overcome these limitations using novel formulation strategies to improve
apigenin delivery.
Several formulation strategies and techniques e.g. liposomes (Arsić et al., 2011), nanocrystal
gel formulations (Al Shaal et al., 2011), and self-micro emulsifying drug delivery systems
(SMEDDS) (Zhao et al., 2013) have been investigated to improve the delivery of apigenin.
Munyendo et al reported that the formulation of D-α-tocopherol acid and polyethylene glycol
1000 succinate (TPGS) stabilized the mixed micelles of apigenin and phospholipids in their

evaluation anticancer properties (Munyendo et al., 2013). Karthivashan et al prepared
‘flavonosomes’ (phytosomes loaded with multiple flavonoids) using phosphatidylcholine as a
carrier, and evaluated their in vitro pharmacokinetics and toxicity (Karthivashan et al., 2016).
Shen et al evaluated a novel topical delivery system for apigenin by using soy lecithin-based
ethosomes (Shen et al., 2014). The authors demonstrated a superior skin targeting with the
prepared ethosomes. Additionally, apigenin-loaded ethosomes also showed a significant
reduction of cyclooxygenase-2 levels in mouse skin inflammation induced by ultraviolet B
(UVB) light. Pawlikowska-Pawlega et al studied the interaction of apigenin within liposomes
formed with dipalmitoylphosphatidylcholine (DPPC) using FTIR spectroscopy, 1H-NMR, and
EPR techniques, and also investigated its chemopreventive activity via changing the fluidity of
tumor cell membranes (Pawlikowska-Pawlega et al., 2013).
While these formulation methods were shown to improve the solubility, dissolution, or in
vitro activity of apigenin , a systematic evaluation of the bioavailability and in vivo
pharmacokinetics of apigenin is missing in literature; this is particularly true for oral
administration of apigenin, or novel formulations of apigenin.
Semalty et al reviewed the potential benefits of pharmacosomes, novel lipid-based drug
delivery systems, in improving the biopharmaceutical properties of several drugs (Semalty et al.,
2009). Previous studies have demonstrated that an appropriate carrier system like phospholipids
can improve the aqueous solubility, permeability, and overall bioavailability of such compounds.
The studies with Centella asiatica (Saoji et al., 2016), matrine (Ruan et al., 2010), oxymatrine
(Yue et al., 2010), curcumin (Zhang et al., 2013), catechin (Semalty et al., 2012), chrysophanol
(Singh et al., 2012), naringenin (Semalty et al., 2014) have shown that molecular aggregation
with phospholipids increased their oral bioavailability by improving the aqueous solubility,

permeability, and other properties of these phytochemicals. Semalty et al discussed the
usefulness of supramolecular phospholipids–polyphenolics adducts (PHYTOSOME®) in
improving the solubility and permeability of low water-soluble polyphenolic compounds across a
broad pharmacological spectrum (Semalty et al., 2010). In a recent review, Semalty A. provided
a comprehensive analysis of cyclodextrin-, and phospholipid-based aggregates in the
enhancement of solubility, dissolution, and overall bioavailability of Biopharmaceutical
Classification System (BCS) Class II and Class IV drugs (Semalty, 2014).
The present work aims to formulate, optimize, characterize an apigenin–phospholipid
phytosome (APLC), and evaluate the optimized formulation for both enhanced aqueous
solubility and oral bioavailability of apigenin in a rat model. Additionally, a preliminary
pharmacological analysis was carried out to evaluate the in vivo antioxidant potential after oral
administration of APLC in rats.
2. Materials and Methods
2.1. Materials
Apigenin was obtained from Shandong Northwest Manufacturing Co., China. Phospholipon®
90H was obtained from Lipoid GmbH, Ludwigshafen, Germany. 1, 4 – dioxane, 2, 2-diphenyl-1picrylhydrazyl (DPPH), 5,5′-dithiobis-2-nitrobenzoic acid (DTNB, Ellman’s Reagent), and 3-(2Pyridyl)-5,6-diphenyl-1,2,4-triazine-p,p′-disulfonic acid monosodium salt hydrate (FerroZine™
Iron Reagent) were obtained from Loba Chemie Pvt. Ltd., Mumbai, India. n-hexane, n-octanol,
thiobarbituric acid, and trichloroacetic acid were purchased from Sigma-Aldrich Corporation, St.
Louis, MO. All other chemicals used were of analytical grade.

2.2. Formulation of apigenin-phospholipid phytosome
The APLC was prepared using different molar ratios of (1:1, 1:2 and 1:3) based on earlier
reported techniques (Bhattacharyya et al., 2014; Maiti et al., 2007). Briefly, accurately weighed
amounts of apigenin and phospholipid were placed into a 100 mL round bottom flask, and
dissolved in 20 mL of a mixture of 1, 4–dioxane:methanol (14:6). The reaction temperature of
the reflux was controlled at 40 ºC, 50 ºC, or 60 ºC using a water bath for two h. The flask
contents were then concentrated to obtain a dry residue. This dried material was dissolved in a 50
mL mixture of chloroform: methanol (45:5). The solution was then concentrated to 2-3 mL and
poured into 100 mL of n-hexane. The resulting APLC was precipitated and filtered.
Subsequently, the phytosome was dried completely under vacuum at 40 ºC. The dried APLC
(yield ~90% w/w) was transferred to a light-protected (amber) glass vial purged with nitrogen,
and stored at room temperature.
2.3. The extent of Apigenin incorporation in the prepared APLC (% yield)
An accurately weighed amount of APLC (equivalent to 10 mg of apigenin) was added to 5 mL of
chloroform. The formed phytosome and the unreacted phospholipid dissolves in chloroform, but
the free (non-aggregated) apigenin remains practically insoluble in chloroform (Tan et al., 2012).
The dispersion was filtered and the free or non–aggregated apigenin was separated as a
precipitate. This non-aggregated apigenin was dissolved in methanol and assayed using a UVvisible spectrophotometer (Model: V-630, JASCO International Co. Ltd., Tokyo, Japan) at 335
nm for apigenin.
2.4. Full-factorial design (32)
A full factorial design was adopted to study the overall influence of specific independent
variables, viz., drug: phospholipids ratio (X1, w: w), and temperature (X2, ºC) on the extent of

apigenin incorporation (% yield). The two independent variables (X1 and X2) were selected at
three levels, coded as -1 (low), 0 (middle), and +1 (higher), resulting in a 32 factorial design of
nine possible combinations. The extent of apigenin incorporation (% yield) was defined as the
dependent variable. The experimental trials were performed using all nine possible combinations
of the selected variables. The mathematical model containing coefficient effects, interactions,
and polynomial terms was analyzed to assess the response using the following equation:

where

is the dependent variable,

effects (

and

is the coefficient of the independent variable . The main

) represent the possible aggregate effect of both factors as they change

independently from their low to high level. The interaction term (

) shows how the response

changes when two factors are simultaneously changed. The polynomial terms (

and

)

describes the non-linearity. The design levels and the real values of the independent variables are
shown in Table 1. The composition of experimental trials along with obtained yield (%) values
are shown in the Table 2.
2.5. Physicochemical characterization
2.5.1. Particle size analysis and zeta potential
Photon Cross-Correlation Spectroscopy (PCCS) with dynamic light scattering was used to
analyze the particle size distribution of the prepared APLC. Briefly, about 5 mg of APLC
powder was dispersed in 10 mL deionized water in a sample vial. The sample vial was inserted
manually into the sample chamber of the analyzer (Model: NANOPHOX, Sympatec GmbH,
Clausthal-Zellerfeld, Germany) with a sensitivity range of 1 nm to10 μm. The count rate was
optimized by selecting an appropriate position of the sample vial with the help of the associated
software. All measurements were carried out at a fixed temperature of 25 ºC.

The zeta potential of the APLC powder was measured using a Dynamic Light Scattering
(DLS) zeta potential and nano particle analyzer (Model: NanoPlusTM-2, Particulate Systems,
Norcross, GA, USA) with a zeta potential range of -200 to +200 mV.
2.5.2. Differential scanning calorimetry (DSC)
The samples of pure apigenin, pure Phospholipon® 90H, the physical mixture (PM) of apigenin
and Phospholipon® 90H, and the APLC were analyzed for their thermal behavior using a
differential scanning calorimeter (Model: DSC-1 821e, Mettler-Toledo AG, Analytical,
Schwerzenbach, Switzerland). Dried nitrogen (50 mL/min) was used as a purge gas. The
instrument was calibrated for the heat flow and heat capacity with high-purity indium standard
using standard procedures reported elsewhere. Each sample (2.0 ± 0.2 mg) followed a single
heating cycle with temperature ramping from 40 °C to 400 °C at a heating rate of 10 °C min-1.
The analysis of the event peaks for all the samples was carried out using the software
accompanying the instrument.
2.5.3. Fourier transform infrared spectroscopy (FTIR)
The molecular interactions between the formulation components were analyzed by obtaining the
infrared scans of pure apigenin, Phospholipon® 90H, PM, and APLC on a FTIR
spectrophotometer (Model: FTIR-8300, Shimadzu Corporation, Kyoto, Japan). Briefly,
individual samples (~2 mg) were uniformly mixed with potassium bromide (KBR, ~200mg) and
compressed under pressure of 10 Ton/nm2 to prepare circular transparent discs. The samples
were previously dried in a hot air oven at 50 °C for 2 h to theoretically remove the influence of
residual moisture, if any. Each analysis included 45 scans, at a resolution of 4 cm−1 in the
wavelength range 4000 to 400 cm−1. The data was analyzed using IRsolution FTIR control
software (version: 1.10) associated with the instrument.

2.5.4. Proton nuclear magnetic resonance (1H-NMR)
The proton nuclear magnetic resonance (1H-NMR) spectra of pure apigenin, pure Phospholipon®
90H, PM, and APLC were obtained on a 400 MHz FT-NMR spectrophotometer (Bruker Avance
II, Bruker BioSpin, Billerica, MA) with a temperature range of -90 °C to 80 °C . All samples
were analyzed at 292 K (18.85 °C).
2.5.5. Powder x-ray diffractometry (PXRD)
The samples of pure apigenin, Phospholipon® 90H, PM, and APLC were analyzed for their
polymorphic state by obtaining their x-ray diffraction scans. This was done using a powder x-ray
diffractometer (Model: D8 ADVANCE, Bruker AXS, Inc., Madison, WI, USA) operating with a
Bragg-Brentano geometry (θ/2θ) optical setup. Briefly, the samples were mounted uniformly as a
thin layer on the sample holder. A one dimensional detector (LYNXEYETM) for x-ray
diffraction, based on Bruker AXS’ compound silicon strip technology was used to monitor
diffraction. The samples were irradiated with a monochromatic CuKβ radiation (λ=1.5406Å) at
an operating voltage and amperage of 30 mV and 10 mA, respectively. The samples were
scanned with the diffraction angle increasing from 3° to 60°, 2θ angle, with a step-angle of 0.04°
2θ and a count time of 5 seconds. The angular spin for the samples was Φ = 360°.
2.5.6. Solubility analysis
The aqueous solubilities of pure apigenin and apigenin in the prepared APLC were determined
by a method similar to that described earlier (Saoji et al., 2016). Briefly, an excess of apigenin or
APLC were added to 5 mL of water or n-octanol in sealed glass containers at room temperature
(25 °C). The liquid was agitated for 24 h, followed by centrifugation for 25 min at 1500 rpm.
The supernatant was filtered through a membrane filter (0.45 µ). 1 mL of this filtrate, after

appropriate dilutions, was assayed using a UV-visible spectrophotometer (Model: V-630,
JASCO International Co. Ltd., Tokyo, Japan) at 335 nm for apigenin.
2.6 Functional characterization
2.6.1

In vitro dissolution studies

The in vitro dissolution behavior of pure apigenin, and apigenin in the prepared APLC was
analyzed using a dialysis method reported earlier (Maiti et al., 2009). Briefly, a dialysis
membrane (LA393, Dialysis Membrane-70, Average diameter 17.5 mm, Average flat width
28.46 mm, and capacity ~ 2.41 mL/cm; HiMedia Laboratories, Mumbai, India), which retains
molecules >12,000 kDa was used to prepare dialysis bags for the samples. The membrane was
washed according to the manufacturer guidelines. 2 mL of apigenin suspension (2 mg/mL) or
APLC (~4 mg apigenin) was added to dialysis bag and tied. The tied membrane bag was
suspended into a beaker containing phosphate buffer saline (PBS, 200 mL, pH 7.4) with
(Tween® 20, 1% w/v). The contents of the beakers were stirred at 50 rpm using a magnetic stirrer
at 37 ± 1°C. At predetermined intervals, 5 mL aliquots were withdrawn and assayed using a UVvisible spectrophotometer (Model: V-630, JASCO International Co. Ltd., Tokyo, Japan) at
335nm to estimate the release of apigenin.
2.6.2 In vivo antioxidant activity
The influence of pure apigenin, and the prepared APLC on the liver function test, and their in vivo
antioxidant activity was evaluated using the method previously reported in literature (Maiti et al., 2007;
Maiti et al., 2009).

2.6.2.1 Animals
Male and female albino rats (Wistar strain, bred in-house, 150-200 g) were employed for the
evaluation of in vivo antioxidant activity of pure apigenin and APLC. All animals were housed in
colony cages in groups of four at controlled temperature (25 ± 5 °C) and humidity (50 ± 5%RH)

conditions, with a 12 h light/dark cycle. The food (pellet chow, Brooke Bond, Lipton, India) and
water were provided ad libitum. The experimental protocol (UDPS/IAEC/2013–14/05, dated
February 14, 2014) for the study was approved by the Institutional Animal Ethics Committee
(IAEC) of the University Department of Pharmaceutical Sciences (UDPS), R. T. M. Nagpur
University, Nagpur, India. The experimental protocols were followed according to the ethical
guidelines provided by the Committee for the Purpose of Control and Supervision of
Experiments on Animals (CPCSEA).
2.6.2.2 Dosing
The animals were divided into four groups, with six animals in each group. Group I and Group II
animals received Tween® 20 (1% v/v, p.o.) diluted with distilled water for seven days. On the
seventh day, Group II animals received a single dose of a mixture of CCl4 and olive oil (1:1, 5
mL/kg, i.p.). Group I served as negative control and Group II served as the positive control.
Group III animals received pure apigenin (25 mg/kg, p.o.) suspension in distilled water with
Tween® 20 (1% v/v) for seven days. On the seventh day, this group also received a single dose of
a mixture of CCl4 and olive oil (1:1, 5 mL/kg, i.p.). Group IV animals received APLC (~25
mg/kg apigenin, p.o.) for seven days. On the seventh day, this group also received a single dose
of a mixture of CCl4 and olive oil (1:1, 5 mL/kg, i.p.). After 24 h of CCl4 administration, all the
animals were anaesthetized using ether. The blood samples of all animals were collected from
the retro orbital plexus and centrifuged. The animals were subsequently euthanized by cervical
decapitation. The supernatant plasma samples were used for the liver function test. Additionally,
the livers of all animals were dissected immediately and washed in ice cold saline. The livers
were homogenized in 0.1 M phosphate buffer saline (PBS, pH 7.4) and centrifuged to obtain a
clear supernatant. This solution was used to estimate the in vivo antioxidant marker enzymes.

2.6.2.3 Liver marker enzyme estimation (liver function test)
The influence of pure apigenin and APLC on rat liver function was evaluated by quantitative
determination of serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic
transaminase (SGPT), serum alkaline phosphatase (SALP), and total bilirubin. A method
previously described in literature was used to estimate SGOT and SGPT levels (Reitman and
Frankel, 1957). Briefly, 0.5 mL of substrate [α-L-alanine (200 mM) for SGOT, or L-aspartate
(200 mM) with 2 mM α-ketoglutarate for SGPT] was incubated for 5 min at 37 °C. 0.1 mL rat
plasma was added to the substrate and the volume was adjusted to 1 mL with sodium phosphate
buffer (pH 7.4, 0.1 M). The mixture was incubated for either 30 min (SGPT) or 60 min (SGOT).
2, 4-dinitrophenylhydrazine (DNPH, 0.5 mL, 1 mM) was then added to this reaction mixture and
left for additional 30 min at room temperature. Finally, 5 mL sodium hydroxide (NaOH, 0.4 N)
was added to the mixture and the resultant solution was analyzed by colorimetry at 505 nm.
SALP levels were estimated using a method previously described by Kind et al. (Kind
and King, 1954). Briefly, 1 mL of substrate was incubated in 1 mL sodium bicarbonate buffer for
3 min at 37 °C. To this solution, 100 μL plasma was added, vortexed, and incubated again for 15
min at 37 °C. After incubation, 0.8 mL sodium hydroxide (0.5 N), 1.2 mL of sodium bicarbonate
(0.5 N), 1 mL aminoantipyrine (0.6% w/v), and 1 mL potassium ferricyanide were added and
mixed well. The absorbance of the resulting mixture was measured at 520 nm.
The total bilirubin in plasma was quantified using the method reported by Malloy et al.
(Malloy and Evelyn, 1937). Briefly, 5 mL of sulfanilic acid solution (4 mmol/L) was added to
0.1 mL of sodium nitrite solution (144 mmol/L). To this solution, 0.25 mL plasma was added.
The mixture was incubated for 10 min at 37 °C and the absorbance measured at 670 nm.

2.6.2.4 In vivo antioxidant marker enzyme estimation
The antioxidant potential of pure apigenin and APLC was assessed by the quantitative estimation
of glutathione (GSH), superoxide dismutase (SOD), catalase (CAT), and lipid peroxidase (LPO).
GSH in rat liver homogenate was estimated using a previously reported method by Ellman
(Ellman, 1959). First, a precipitating mixture was prepared by dissolving 1.67 g metaphosphoric
acid, 0.2 g EDTA, and 30 g NaCl in distilled water to make up 100 mL aqueous solution.
Following the Ellman protocol, 0.2 mL rat liver homogenate, 1.8 mL distilled water, and 0.3 mL
precipitating mixture were combined and centrifuged at 5000 rpm for 5 min to separate proteins.
To 1 mL of the supernatant, 1.5 mL phosphate buffer (0.1 M) and 0.5 mL DTNB reagent were
added. The contents was mixed in a vial and the absorbance of the solution was measured at 412
nm using UV-visible spectrophotometer (Model: V-630, JASCO International Co. Ltd., Tokyo,
Japan). The concentration of GSH was expressed as μg/mg of protein.
A method described by Marklund et al. was used to quantitatively estimate SOD in rat
liver homogenate (Marklund and Marklund, 1974). Briefly, a reaction mixture was prepared by
the addition of 2 mL Tris-HCl buffer (75 mM, pH 8.2), 0.6 mL EDTA (6 mM), 20 µL rat liver
homogenate, and 0.5 mL freshly prepared pyrogallol solution (30 mM). An increase in
absorbance and change in absorbance/min for the resulting solution was measured against blank
for 3 min at 30 second intervals at 420 nm using UV–visible spectrophotometer (Model: V-630,
JASCO International Co. Ltd., Tokyo, Japan). One unit of enzyme activity is considered
equivalent to 50% inhibition in the rate of auto-oxidation of pyrogallol. The activity of SOD was
expressed as units/mg of protein.
Lipid peroxidase (LPO) in rat liver homogenate was estimated using the method of
Stocks et al. (Stocks and Dormandy, 1971). To a vial, 0.5 mL rat liver homogenate, 0.2 mL

sodium lauryl sulfate (8.1% w/v), 1 mL trichloroacetic acid (20% w/v), and 1.5 mL
thiobarbituric acid (0.8%, w/v) were mixed. This mixture was heated at 100 ºC for 1 h. The
mixture was then allowed to cool to room temperature (25 ºC) and 1 mL of distilled water was
added. Centrifugation of the mixture at 4000 rpm for 10 min helped separate the organic layer.
The absorbance of organic layer was measured at 532 nm using UV–visible spectrophotometer
(Model: V-630, JASCO International Co. Ltd., Tokyo, Japan). The lipid peroxidation was
calculated on the basis of the molar extinction coefficient of malondialdehyde (MDA) (1.56 x
105 M-1 cm-1), and presented in terms of MDA (nM/g) in hemoglobin.
CAT was quantitatively estimated using the method reported by Beers et al. (Beers and
Sizer, 1952). Briefly, in a cuvette, 0.1 mL rat liver homogenate and 1.9 mL phosphate buffer (50
mM, pH 7.4) were added. The reaction was initiated by the addition of 1.0 mL of freshly
prepared hydrogen peroxide (H2O2, 30 mM). The decomposition rate of H2O2 was measured at
240 nm using a UV–visible spectrophotometer (Model: V-630, JASCO International Co. Ltd.,
Tokyo, Japan).
2.6.2.5 Histopathological studies
At the end of the treatment period, animals from all four treatment groups were euthanized and
their livers dissected. The isolated livers were maintained in a buffered formalin (10% v/v)
solution. The livers were then carefully sectioned and stained with hematoxylin and eosin
reagent. The liver sections were examined under an optical microscope (Model: DM2500, Leica
Microsystems Inc., Buffalo Grove, IL). The images were captured at a magnification of 400×
with the attached digital camera.

2.6.3

Oral bioavailability studies

2.6.3.1 LC-MS/MS analysis method
A LC-MS/MS analytical method previously reported in the literature was followed for the
quantitative evaluation of samples (Duan et al., 2011). The instrument employed for the study
was a triple quadrupole mass spectrometer (Model: Thermo Scientific™ TSQ Quantum™
Access MAX, Thermo Fisher Scientific Inc., Waltham, MA, USA), equipped with an online
degasser, column heater, and an auto sampler. The stationary phase consisted of a C18 HPLC
column (100 mm x 4.6 mm, Thermo Scientific™ Hypersil GOLD™, Thermo Fisher Scientific
Inc., Waltham, MA, USA) with a particle size of 5 µm and maintained at 25 °C. The mobile
phase consisted of methanol with formic acid (0.1% v/v) and the flow rate was fixed at 1.5
mL/min. To achieve the best possible resolution of apigenin peaks, the method was standardized
using quercetin as the internal standard. Chromatographic peaks were detected at 360 nm for
quantitative analysis. The mass spectrometric analysis of the samples was carried out in a
positive ionization mode using the selected reaction monitoring (SRM). The ion source
temperature was 500 °C. The target ions were monitored at m/z of 271.22 for apigenin and
303.01 for quercetin. The data acquisition, peak integration, and other analysis was performed
using the associated software (Thermo Scientific™ LCQUAN™, version 2.6, Thermo Fisher
Scientific Inc., Waltham, MA, USA).
2.6.3.2 Extraction of apigenin from plasma and sample preparation
A sample preparation technique previously reported by Chen et al. (Chen et al., 2007) was used
for the study. Briefly, the laboratory animals were fasted for 12 h with free access to water. The
animals divided into two groups of six animals each. Group I received a single dose of apigenin
(100 mg/kg, p.o.) and group II received a single dose of APLC (100 mg/kg, p.o.). At

predetermined time intervals, the animals were anesthetized and blood samples obtained from
the retro-orbital plexus were collected into Eppendorf® Safe-Lock microcentrifuge tubes (1.5
mL). The blood samples were then centrifuged at 3000 g for 10 min, the plasma separated,
collected, and stored at -20 °C prior to analysis.
For the extraction of apigenin from rat plasma, plasma samples (100 μL) were transferred
to a test tube and hydrochloric acid (2.0 M) was added to it. The mixture was hydrolyzed at 80
°C for 1.5 h. After allowing to cool to room temperature1.0 mL ethyl acetate containing
quercetin (0.05 μg/mL) was added to this reaction mixture. The mixture was vortexed for 3 min
and then centrifuged at 3500 g for 10 min. After centrifugation, 0.8 mL of the supernatant
organic phase was transferred to a separate test tube and dried in a vacuum desiccator at room
temperature. The dried sample was then reconstituted in the mobile phase (100 μL) and analyzed
by the LC-MS/MS method described above.
2.6.3.3 Pharmacokinetic studies
The pharmacokinetic parameters, i.e. maximum plasma concentration (Cmax) and time to reach
maximum concentration (Tmax), were obtained directly from the concentration–time curve. Other
parameters such as half-life (t1/2), area under the plasma concentration-time curve from zero to
the time of the final measured sample (AUC0-t), area under the plasma concentration-time curve
from zero to infinity (AUC0-∞), clearance (cl/F) and volume of distribution (Vz/F), and the
relative bioavailability (F) were calculated using a statistical software (WinNonlin®, Version 4.1,
Certara USA Inc., Princeton, NJ, USA).
2.7 Statistical analysis
The aqueous solubility and in vitro results are presented as mean ± standard deviation. The
results from the liver function test, in vivo antioxidant activity, and the pharmacokinetic analysis

are presented as mean ± standard error of mean. The statistical analysis was carried out using
one-way analysis of variance (ANOVA) followed by Dunnett’s and Student’s t-test. p values <
0.05 were assumed as statistically significant.
3

Results and discussion

3.1 Formulation of apigenin-phospholipids molecular aggregates (Phytosome)
Flavonoids are generally lipophilic molecules and easily soluble in organic solvents (Jabbari and
Gharib, 2012). This physical property is exploited in the current study using the solvent
evaporation method to create a stable phytosome of the flavonoid molecule with phospholipids.
Existing literature on flavonoids describe the creation of flavonoid-phospholipid aggregates
using dichloromethane (DCM) in the solvent evaporation method (Bhattacharyya et al., 2014).
However, we found that apigenin possesses poor solubility in DCM resulting in the precipitation
of the APLC from DCM. Therefore, the solubility of apigenin and the extent of apigenin
incorporation was assessed using other solvents. 1, 4-dioxane is an aprotic solvent with low
dielectric constant, and may assist in solubilization of apigenin and phospholipids to result in the
formation of stable APLC. We found the binary solvent combination of 1, 4-dioxane: methanol
(14:6) to be an optimal solvent system for preparing the APLC. Note: The solvent, 1, 4-dioxane
is used in this study solely for technical reasons, i.e. solubilizing of the formulation
components. Due to the reported toxicity profile of 1, 4-dioxane in humans, it is strongly
recommended that alternative solvent be explored for further development and/or
commercial manufacture of pharmaceutical formulations (Agency for Toxic Substances &
Disease Registry, 2012).

3.2 Full-factorial design (32)
The results of the extent of apigenin incorporation (% yield) from the experimental trials carried
out using a 32 full factorial design are shown in Table 2. The results indicated that the extent of
apigenin incorporation was significantly influenced by both the variables studied, i.e. apigenin:
phospholipid ratio (X1, w:w) and the reaction temperature (X2, °C). For the nine experimental
batches examined (with different combination of variables), the observed extent of apigenin
incorporation ranged between 67 and 94%. These data were used to construct a quadratic model
relating the extent of apigenin incorporation (yield, %) to the tested variables. The resulting
polynomial equation (Eq. 1, below) was used to draw conclusions based on the magnitude of the
coefficient, as well as the sign (+, or –) associated with it.

The estimated coefficient value of b0, b1, b2, and b3 were found to be statistically significant (p <
0.05), whereas b4 and b5 were found to be not significant (p < 0.05). These observations, coupled
with the observed value of the correlation coefficient (R2 = 0.9989), lead us to conclude that this
was the best representative model for the study. The positive sign associated with coefficients (b1
and b2) indicated a positive correlation between the studied variables and the yield (%). The
influence of the studied variables on the yield (%) is also shown in the form of response surface
and contour plot (Figure 1). Based on these observations, along with calculations from the
developed quadratic model, the optimal values for the studied variables, i.e. drug: phospholipid
ratio (X1, w:w) and the reaction temperature (X2, °C) were found to be 1:2, and 60°C,
respectively.

3.3 Validation of the optimized model
An additional batch of APLC was prepared in order to validate the model using the optimized
values of the variables,. A comparison between the predicted (theoretical) yield (%) of the APLC
obtained from the developed model and the actual yield (%) achieved from the prepared
formulation was carried out. The model-predicted value for the average yield (%) of apigenin in
the optimized APLC was 93.7%, while the actual yield (%) from the prepared batch was found to
be 94.87 ± 0.93 %., indicating both applicability, and validity of the developed model. The bias
(%), calculated using the equation (2) below, was also found to be lower than 3% (-1.25%),
indicating the relative robustness of the model (Qin et al., 2010).

3.4 Physicochemical characterization
3.4.1 Particle size analysis and zeta potential
Particle size and zeta potential are valuable predictors of effective distribution and physical
stability of nanoparticles in a liquid medium. According to Tan et al (Tan et al., 2012), the
particle size (246.1 nm) of evodiamine–phospholipids complex played a major role in sustained
release as well as enhancing oral absorption efficiency of evodiamine. Previously published
reports have suggested that lymphatics play a role in the transport of larger particles (≤ 5 mm)
whereas, endocytosis is a major pathway for the transport of the smaller particles (≤ 500 nm)
(LeFevre et al., 1978; Savic et al., 2003). In the present study, the mean particle size of 107.08 ±
1.30 nm, with polydispersity index of 0.37 ± 0.012 for APLC is appropriate for oral drug
delivery. The low polydispersity index indicates a narrow range of particle size distribution.
Zeta potential (ζ) is a measure of stability of a colloidal dispersion. The zeta potential
value (-22.35 ± 0.30 mV) obtained for APLC was greater than -30 mV, which indicates excellent

stability of the APLC from flocculation when seen in the context of its low particle size. The zeta
potential with range (-20 to 30 mV) was earlier demonstrated as a characteristic property of zeta
potential for attraction followed by flocculation exceeding repulsion forces (Dhore et al., 2016;
Freitas and Müller, 1998). The zeta potential value depends on the type and composition of
phospholipids. In APLC, the low zeta potential value can be elucidated that, the involvement of
portion phospholipids with generation of negative charge in aqueous environment with
somewhat neutral pH. Hence, with smaller particle size, lower polydispersity index and modest
zeta potential value suggested a good physical stability for APLC.
3.4.2 Differential scanning calorimetry (DSC)
Differential scanning calorimetry is a well-established techniques for the analysis of thermal
behavior of a wide variety of materials. Measuring changes in material properties as a function of
controlled changes in the temperature can provide useful information regarding the melting,
degradation, compatibility, stability, and other related properties of test materials. In DSC
thermograms these changes exhibit themselves as enthalpy changes, appearance/disappearance
of peaks, and changes to a peak’s onset time, shape, and relative area. It also provides
information of drug-excipient interactions and formation of new entities.
Figure 2 (A, B, C, and D) shows the DSC thermograms of pure apigenin, pure
Phospholipon® 90H, PM, and APLC, respectively. Pure apigenin (Figure 2A) exhibited a sharp
endothermic (melting) peak at 360.82 ºC, indicating crystalline nature and purity of apigenin.
The thermograms of Phospholipon® 90H (Figure 2B) showed two distinct peaks, first peak of
lower intensity at 67.16º C and a second relatively sharper peak at 84.83º C. While the intensity
of the first peak can be attributed to the melting, the shape of the second peak indicates a phasetransition point. This is suggestive of a change from a gel state to a liquid crystalline state, and

accompanied by isomeric changes to the hydrocarbon segment of the phospholipid, thought to be
caused due to movements of the polar segment of phospholipid molecule at increasing
temperatures (Li et al., 2013; Yanyu et al., 2006). The thermogram of the physical mixture (PM)
(Figure 2C) also shows two dissimilar peaks, i.e. a smaller endothermic peak at 68.34 ºC, and a
broader peak at 84.84º C. It may be inferred that controlled increase in temperature may cause
individual components to melt, and form a partial aggregates in situ, whose melting point is
lower than apigenin or phospholipid (Ruan et al., 2010). Finally, the thermograms of APLC
(Figure 2D) revealed a completely new peak at 75.05º C, and an the original peaks of apigenin
and phospholipids appeared to be absent (Galasso et al., 2006). These results are consistent with
the previously published reports. Thus, on the basis of comparison of above four DSC
thermograms and previous reports it can be concluded that a stable APLC was formed by weak
intermolecular interactions (hydrogen bonding, van der Waals interactions, etc.) between
apigenin and Phospholipon® 90H (Lasonder and Weringa, 1990; Venema and Weringa, 1988;
Yanyu et al., 2006). These interactions possibly allow the fatty acid chains of the phospholipid
molecule rotate freely and surround the apigenin molecule, thus dispersing the apigenin molecule
into the phospholipid molecule at a molecular level.
3.4.3 Fourier transform infrared spectroscopy (FTIR)
The FTIR spectra of pure apigenin, pure Phospholipon® 90H, PM, and APLC are shown in
Figure 3A, 3B, 3C, and 3D, respectively (all units are cm-1). The spectra of pure apigenin (Figure
3A) revealed characteristic peaks at 3272.34 (O-H), 2894.31 (C-H), 2827.31 (C-H), 1606.77
(C=O), 1622.10 (C=C), 1557.59 (C=C), and 1500.68 (C=C). These observations were in
agreement with those reported earlier (Siniša Đorđević et al., 2000). The FTIR spectrum of pure
Phospholipon® 90H (Figure 3B) revealed the characteristic signals at 2918 and 2850, related to

the C–H stretching present in the long fatty acid chain. Additional signals were also observed at
1738 (C=O stretching in the fatty acid ester), 1236 (P=O stretching), 1091 (P–O–C stretching),
and 970 [-N+(CH2)3] (Semalty et al., 2012). The spectra of the physical mixture (PM) (Figure
3C) showed peaks that were characteristic of the individual components, i.e. apigenin and
Phospholipon® 90H at 3304.20, 2917.46, 2849.95, and 1268.25. The spectra of APLC showed
broad peaks at 3337.96 (O-H stretching in apigenin), 1237.39 (P=O stretching), and 1092.72 (PO-C bending). Comparison of the FTIR spectra shows the changes to specific regions of the
apigenin molecules due to interaction with phospholipids. Changes to the stretching frequency of
the phenolic O-H of apigenin from 3272.34 to 3337.96 in the phytosome suggests that weak
intermolecular interactions have been created during the formation of APLC. Moreover, the
absorption peaks of phospholipids at 1237.39 and 1092.72 were altered completely. It can thus
be inferred that weak intermolecular interactions between apigenin and phospholipid molecules
are attributable to the formation of APLC.
3.4.4 Proton nuclear magnetic resonance (1H-NMR)
Figure 4 (A and B) shows 1H–NMR spectra of pure apigenin and the prepared APLC,
respectively. 1H chemical shifts are reported in parts per million relative to the TMS peak at
δ0.00. The spectrum of apigenin exhibited characteristic H-shifts described below: 1H NMR (400
MHz, DMSO-d6): δ12.93 (s, 1 H, 5-OH), 10.73 (s, 1 H, 4’-OH), 10.28 (s, 1 H, 7-OH), 7.88 (d, J
= 8.68 Hz, 2 H, H-2′, H-6′), 6.92 (d, J = 8.68 Hz, 2 H, H-3′, H-5′), 6.71 (s, 1 H, H-3), 6.44 (d, J =
1.76 Hz, 1 H, H-8), 6.18 (d, J = 1.76 Hz,1 H, H-6). These chemical shifts were compared with
and were found to be consistent with those of pure apigenin established in literature (Li et al.,
1997; Semalty et al., 2012) The NMR of Phospholipon® 90H (Sharma et al., 2015): 1H NMR
(400 MHz, DMSO-d6) δ 4.85 (1H, s), 4.08-3.96 (1H, m), 3.83-3.62, (2H, m), 3.38 (1H, s), 3.07

(15H, s), 2.95 (8H, d, J = 6.8 Hz), 2.27, (1H, s), 1.91 (2H, m), 1.26 (2H, s), 0.95 (23H, s), 0.57
(3H, s). The 1H NMR of APLC is as follows: δ12.92 (s, 1 H, 5-OH), 10.70 (s, 1 H, 4’-OH), 10.39
(s, 1 H, 7-OH), 8.225 (2H), 7.88 (d, J = 8.68 Hz, 2 H, H-2′, H-6′), 7.86, 6.93 (d, J = 8.68 Hz, 2
H, H-3′, H-5′), 6.71 (s, 1 H, H-3), 6.44 (d, J = 1.76 Hz, 1 H, H-8), 6.18 (d, J = 1.76 Hz,1 H, H-6),
3.17 (s, 3H), 1.23 (s, 3H). Upon comparison of the chemical shifts of apigenin alongside APLC,
the key differences emerge in the downfield aromatic region (δ>7) and the upfield aromatic
region (δ<4). The alkyl side chain of the APLC is seen at δ1.23 and the N-methyl groups
correspond to the chemical shift at δ 3.17 (Sikarwar et al., 2008). The formation of molecular
aggregates with apigenin is clearly seen by the change in proton signals in the aromatic region.
The charged head of the phospholipid molecule is involved in weak intermolecular interactions
such as hydrogen bond and ion-dipole interactions with the phenolic (4’-OH and 5-OH) regions
of apigenin. This is supported by the lowered intensity of these proton signals and their distinct
downfield chemical shifts. This indicates the embedding of apigenin in the phospholipid and thus
confirms the formation of the APLC.
3.4.5

Powder x-ray diffractometry (PXRD)

The x-ray diffractograms of pure apigenin, pure Phospholipon® 90H, PM, and APLC are shown
in Figure 5 (A, B, C, and D, respectively). The diffraction patterns of pure apigenin (Figure 5A)
displayed intense and sharp crystalline peaks at 2θ = 11º, 14º, 16º, 24º, 25º, and 26º,
characteristic of the crystalline nature of apigenin. Phospholipon® 90H (Figure 5B) exhibited a
single, relatively broad peak around 2θ = 20.1º. The absence of any additional well-defined,
sharp, crystalline peaks in the Phospholipon® 90H diffractogram indicated the amorphous nature
of the phospholipid molecule. These observations are consistent with previously published
reports (Cai et al., 2012). The diffractogram of physical mixture (Figure 5C) exhibited few
crystalline peaks (related to apigenin) with lower intensity, and a broader peak (associated with

Phospholipon® 90H). The decrease in the intensity of crystalline could be due to the lower
amount of apigenin in the mixture, interference by the phospholipid molecule, or in situ
formation of a partial aggregates between apigenin and phospholipid, indicating a partial loss of
the crystalline nature of apigenin (Cai et al., 2012). Finally, the diffractogram of APLC exhibited
a single broad peak at 2θ = 20.8º, and this diffractogram was similar to that of Phospholipon®
90H, suggesting that apigenin in APLC may be molecularly dispersed in phospholipid matrix,
and may be present in an amorphous form (Yue et al., 2008).
3.4.6 Solubility analysis
The results of the measured solubilities of the pure apigenin, PM, and APLC in water and noctanol are shown in the Table 4. Pure apigenin was observed to have poor aqueous solubility
(~0.6 µg/mL), and a relatively higher solubility in n-octanol (~600 µg/mL), indicating a rather
lipophilic nature. The physical mixture (PM) revealed a modest, but significant increase in the noctanol solubility (~635 µg/mL), and a substantial increase (~10-fold) in the aqueous solubility
compared to that of pure apigenin (p < 0.01). The prepared phytosome (APLC) however, showed
a dramatic, and a highly significant (over 35-fold) increase in the aqueous solubility compared to
that of pure apigenin (p < 0.001). Partial amorphization (reduced molecular crystallinity) of the
apigenin, and the overall amphiphilic nature of the prepared phytosome can be attributed as the
main reasons for this observed increase in aqueous solubility (Singh et al., 2012; Xia et al.,
2013).
3.5 Functional characterization
3.5.1 In vitro dissolution studies
Figure 6 compares the dissolution behavior of pure apigenin with that of the prepared APLC in
phosphate buffer (pH 7.0). The release profiles of apigenin and APLC were found to be similar

for the first 5 h. After this point, apigenin dissolution appeared to reach a plateau reaching a
maximum of 27.86 % in 8 h. In contrast, the release of apigenin from the APLC continued to
increase reaching 50.98% after 12 h. The difference in release rate of apigenin from the two
formulations can be attributed to the increased solubility and increased wettability of apigenin in
the prepared phytosome (Perrut et al., 2005). Accordingly, (a) pure apigenin has low aqueous
solubility which is shown to be improved by the amphiphilic nature of Phospholipon® 90H; (b)
apigenin is assumed to change from a crystalline state to a partially amorphous state in the
APLC, which may extend the rate and extent of dissolution to 12 h; and (c) a change in the
structural morphology of crystalline apigenin and the amphiphilic nature of Phospholipon® 90H
allows for greater wetting of APLC and improved dispersion. Moreover, the sustained release of
apigenin from APLC may be assumed to occur via a two-step diffusion process. First, in the
presence of aqueous media, apigenin molecules dissociates from the phytosome. Second, the
dissociated free apigenin molecules diffuses out of the phospholipid matrix (Dash et al., 2010).
Thus, APLC was found to significantly enhance both the rate and the extent of apigenin release
compared to pure apigenin.
3.5.2 In vivo antioxidant activity
3.5.2.1

Liver function test

Carbon tetrachloride (CCl4) is a well-known hepatotoxin used in animal models. Carbon
tetrachloride is reported to be metabolized by hepatic CYP450 enzymes into reactive oxidative
species which affect vital organs such as the heart, kidney, brain, blood, and liver (Khan et al.,
2012). Free radicals generated from the xenobiotic transformation of carbon tetrachloride (CCl4)
bind covalently to cellular macromolecules (e.g. lipids, nucleic acids, proteins) resulting in
oxidative damage. The results of the influence of apigenin and APLC on the hepatic markers of
CCl4-induced rat liver damage are described in Table 5. A significant increase in the marker

enzymes viz., SGOT, SGPT, SALP, and total bilirubin was observed in livers of rats treated with
CCl4 alone. The administration of apigenin (25 mg/kg, p.o.) for 7 consecutive days prevented
significantly (p < 0.05) this increase in all marker enzymes except SGPT. The administration of
APLC (~25 mg/kg apigenin) also prevented the CCl4-induced increase in the levels of all liver
marker enzymes (including SGPT), and with higher significance (p < 0.01). The results thus
demonstrate improved hepatoprotective activity of APLC compared to that observed with pure
apigenin.
3.5.2.2 In vivo antioxidant marker enzyme estimation
Levels of liver enzymes such as glutathione (GSH), superoxide dismutase (SOD), catalase
(CAT), and lipid peroxidase (LPO) have been reported as reliable indicators of antioxidant
activity (Khan et al., 2012; Maiti et al., 2005; Recknagel et al., 1989). Apigenin has been
documented as having excellent antioxidant and hepatoprotective properties (Romanova et al.,
2001). In the current study, we examine the effects of pure apigenin and APLC on the levels of
GSH, SOD, CAT, and LPO on CCl4-treated and naïve mice (Figure 7). CCl4-treated animals
showed significantly reduced (p < 0.01) levels of GSH compared to the control group of normal
animals. The group treated with pure apigenin (25 mg/kg, p.o.) significantly (p < 0.05) prevented
the CCl4-induced reduction in GSH levels. The animal group treated with APLC (~25 mg/kg
apigenin, p.o.) also showed a prevention of CCl4-induced lowering of GSH levels, albeit with a
higher significance (p < 0.01) in the liver homogenate. The levels of SOD were found to be
significantly (p < 0.01) reduced as a result of CCl4 treatment. Treatment with pure apigenin (25
mg/kg, p.o.) failed to significantly prevent CCl4-induced reduction in SOD levels. In
comparison, the APLC (~25 mg/kg apigenin, p.o.) treatment was found to result in a significant
(p < 0.01) prevention of CCl4-induced lowering of SOD levels. CAT levels were found to

significantly (p < 0.01) decrease as a result of CCl4 treatment. CCl4-treated animals showed
significantly reduced (**p < 0.01) CAT level as compared to normal animals. The group treated
with pure apigenin (25 mg/kg, p.o.) significantly (p < 0.05) prevented this CCl4-induced
reduction in CAT levels. The animal group treated with APLC (~25 mg/kg apigenin, p.o.) also
showed a prevention of CCl4-induced lowering of CAT levels, albeit with a higher significance
(p < 0.01). CCl4 treatment was found to result in significantly (p < 0.01) increased LPO levels
when compared to normal rats. The group treated with pure apigenin (25 mg/kg, p.o.)
significantly (p < 0.05) prevented this CCl4-induced increase in LPO levels. The animal group
treated with APLC (~25 mg/kg apigenin, p.o.) also showed a prevention of CCl4-induced
increase of LPO levels, albeit with a higher significance (p < 0.01).
3.5.2.3 Histopathological studies

A visual assessment of the influence of pure apigenin or APLC treatment on the CCl4-induced
liver damage was provided by the histopathological investigation of rat liver tissues. Figure 8 (A,
B, C, and D) shows hematoxylin-eosin stained microscopic (400×) images of liver tissues for the
treatment groups, i.e. Tween® 20, CCl4-treated, pure apigenin + CCl4, or APLC+ CCl4,
respectively. As shown in Figure 8A, the treatment group that received Tween® 20 (1%, v/v)
exhibited well-preserved cellular organelles indicating healthy, well-functioning liver tissue and
hepatic cells. The animals treated with CCl4 alone (Figure 8B) showed visible damage and
degeneration of parenchymal cells, degeneration of the fatty tissues (steatosis), and a significant
damage to the central lobular region. The administration of pure apigenin (25 mg/kg, p.o.)
demonstrated a hepatoprotective activity against the CCl4-induced hepatic toxicity (Figure 8C).
Similarly, the treatment group that received APLC (~25 mg/kg apigenin, p.o.) showed a
significant protection against CCl4-induced liver damages (Figure 8D). Both pure apigenin and

APLC treatments appear to restore the normal anatomy of the hepatic cellular structures, which
can be attributed to the antioxidant properties of apigenin.
3.5.3 Oral bioavailability studies
The chromatographic conditions were optimized to improve peak resolution, signal-to-noise
ratio, and the duration of sample analysis. Apigenin and quercetin (internal standard) are polar
molecules and different buffers were tested to obtain a mobile phase that produced optimal
sensitivity and efficiency. Methanol was used as mobile phase and the samples analyzed by LCMS/MS with an acceptable run of 5.0 min. We observed that adding formic acid (0.1% v/v) to
the mobile phase greatly improved the electrospray ionization efficiency of the analytes in the
positive ion mode. An initial UV scan revealed two peaks for apigenin (268 nm and 335 nm),
and a single peak for quercetin (368 nm). The choice of an appropriate detection wavelength (λ)
is critical to ensure a reliable detection of all components of the analyte. Consequently, 350 nm
was selected as the wavelength of detection for current analysis.
Apigenin was initially characterized according to its mass spectra from a syringe pump
infusion analysis, and the daughter ions were revealed in SRM. The heated-electrospray
ionization (H-ESI) was employed for improved sensitivity and fragmentation. We observed that
the optimum de-clustering potential for apigenin was +4500V, and thus positive ion mode was
found to be more sensitive for the analysis of apigenin. We also found that it was ideal to use the
SRM mode was ideal. In this mode only the daughter ions of apigenin and quercetin were
fragmented at a collision energy of 39V using nitrogen as a collision medium. In the full-scan
mass spectra, the daughter ions were observed to be stable and exhibited a high abundance. The
daughter ions were thus selected as precursor ions for MS/MS fragmentation analysis of apigenin

and quercetin. The optimized mass transition ion–pairs (m/z) for quantification of apigenin and
quercetin were established at 271.2/119.0 and 303.0/152.9, respectively.
The liquid–liquid extraction, protein precipitation, and solid–liquid extraction are among
the commonly used techniques for extraction of drugs from a plasma matrix. Solid-liquid
extraction demonstrates excellent recovery and reproducibility. However this technique is
complicated and expensive. This limits its applications for a rapid processing of multiple
samples for bioequivalence and pharmacokinetics studies (Yang et al., 2013). The protein
precipitation technique exhibits low sample recovery and higher costs due to the use of multiple
extracting solvents (Barve et al., 2009; DuPont et al., 2004). In the current study, liquid-liquid
extraction using hydrochloric acid (0.2M) was used to process the plasma samples. During the
experimental trials, we found that the apigenin and quercetin were easily detected after
hydrolysis of the plasma with high recovery and accuracy (Chen et al., 2010; Chen et al., 2012;
Duan et al., 2011). The LC-MS/MS technique was thus effectively applied to monitor the
concentrations of apigenin in rat plasma for pharmacokinetic evaluation.
The mean plasma concentration-time profiles of apigenin in the plasma of animals treated
with pure apigenin (100 mg/kg, p.o.) or APLC (~100 mg/kg apigenin, p.o.) are shown in Figure
9. The results show a significant increase in the plasma concentration of apigenin in groups
treated with APLC up to 10 h. The plasma concentration-time profiles of both treatment groups,
i.e. pure apigenin and APLC showed a bimodal pattern. These results are in agreement with
previous reports where, this bimodal profiles are thought to occur due to enterohepatic
recirculation (Wan et al., 2007; Zhang et al., 2009). The key pharmacokinetic parameters, as
estimated using a statistical software (WinNonlin®, Version 4.1, Certara USA Inc., Princeton,
NJ, USA) are listed in Table 6. The analysis of data revealed that all pharmacokinetic parameters

indicative of relative bioavailability, i.e. Cmax, Tmax, and AUC0-∞ were significantly higher in
animals treated with APLC compared to those treated with pure apigenin. The values of
elimination half-life (t1/2el) and the elimination rate constant (Kel) remained unchanged for both
treatment groups. The clearance (cl/F) and volume of distribution (Vz/F) of apigenin was found
to be significantly lower in the group treated with APLC. These observations indicated a longer
residence and resulting prolonged duration of action of apigenin after APLC administration. The
computed bioavailability (F) of apigenin after APLC administration was found to be 82.02%.
The observed enhancement of the relative bioavailability of apigenin after single oral
administration of APLC can be attributed to two main factors: (1) phospholipid-based formation
of molecular aggregates which improves the aqueous solubility of apigenin, leading to enhanced
intestinal absorption, and, (2) the role of amphiphilic phospholipids as a vesicular carrier matrix
for apigenin, which may protect it from hepatic first-pass metabolism. While we have observed
an improved in vivo bioavailability of apigenin with the prepared APLC, it is important to note
that several factors e.g. dietary lipid intake, can significantly influence the rate and extent of
absorption and the overall bioavailability of drugs via these systems. As pointed out by Fong et.
al, the evaluation of solubility and permeability, and the use of appropriate biorelevant media for
such evaluation is critical in understanding the biopharmaceutical behavior of lipid-based
formulations (Fong et al., 2016).
4

Conclusions

The present work reveals the excellent potential of phospholipid-base molecular aggregates for
improving the solubility, oral bioavailability and in vivo antioxidant activity of apigenin, a BCS
Class II drug. The APLC was formulated with the help of a solvent evaporation method and
optimized using a full factorial design (32) strategy. The APLC formation was supported by

DSC, FTIR, 1H-NMR, and PXRD analysis. The data clearly pointed towards the presence of
non-covalent bonding interactions, viz, hydrogen bonding, ion-dipole and van der Waals
interactions, as key factors in the formation of a stable APLC. Solubility studies demonstrated
increased solubility of APLC in water as compared to PM or pure apigenin. Furthermore, the rate
and extent of in vitro apigenin release was significantly enhanced when compared to the
suspension of pure apigenin. In a CCl4-induced hepatotoxicity model in rats, APLC restored the
antioxidant enzymes to a significant level, relative to free apigenin. APLC also enhanced oral
bioavailability of apigenin by demonstrating increased Cmax, Tmax, and AUC parameters as
compared to apigenin. This study validates the value of employing phospholipids in preparing
phytosomes with phytoconstituents of low solubility to improve their solubility, oral
bioavailability, and pharmacological properties.
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Figure legend
Figure 1. The response surface plot and contour plots of entrapment efficiency (Y, %) as a
function of the ratio of apigenin and Phospholipon® 90H (X1, w:w), and the reaction temperature
(X2, °C).

Figure 2. DSC thermograms of (A) pure apigenin, (B) Phospholipon® 90H, (C) the physical
mixture (1:1) of apigenin and Phospholipon® 90H, and (D) APLC.

Figure 3. FTIR spectra of (A) pure apigenin, (B) Phospholipon® 90H, (C) the physical mixture
(1:1) of apigenin and Phospholipon® 90H, and (D) APLC.

Figure 4. 1H-NMR spectra of (A) apigenin, and (B) APLC.

Figure 5. The X-ray diffractograms of (A) pure apigenin, (B) Phospholipon® 90H, (C) the
physical mixture (1:1) of apigenin and Phospholipon® 90H, and (D) APLC.

Figure 6. The in-vitro dissolution profiles of apigenin release from apigenin suspension, and
APLC. Values are mean ± Std. Dev. (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001 (significant
with respect to pure apigenin).

Figure 7. Influence of pure apigenin and APLC on rat liver antioxidant marker enzymes, i.e.
glutathione reductase (GSH) (nmoles/mg of protein), superoxide dismutase (SOD) (units/mg
protein), catalase (CAT) (units/mg protein), and lipid peroxidase (LPO) (nmoles of MDA

released /g tissue). Values are Mean ± Std. Error of Mean (n = 6). *p < 0.05, **p < 0.01
(significant with respect to control: CCl4-only treated groups).

Figure 8. Histopathology micrographs (×400) of rat livers. (A) Normal: Tween® 20 (1%, v/v,
p.o.), (B) Control: CCL4 + olive oil (1:1, 5 mL/kg, i.p.), (C) Pure apigenin (25 mg/kg, p.o.) +
[CCL4 + olive oil (1:1, 5 mL/kg, i.p., day 7)], and (D) APLC (~25 mg/kg apigenin, p.o.) + [CCL4
+ olive oil (1:1, 5 mL/kg, i.p., day 7)].

Figure 9. Mean plasma concentration-time profile after oral administration of pure apigenin (100
mg/kg, p.o.) or APLC (~100 mg/kg apigenin, p.o.). Values are mean ± Std. Dev. (n = 6). *p <
0.05; **p < 0.01, and ***p < 0.001 (significant with respect to pure apigenin treated group).
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Tables
Table 1. Coded levels and “Real” values for each factor studied
Levels
-1
0 +1
Independent
Real values
Apigenin : Phospholipid ratio (X1, w:w) 1:1 1:2 1:3
Reaction temperature (X2, °C)
40 50 60
Dependent
Extent of apigenin incorporation or Yield (Y, % w/w)
Variables

Table 2. Full factorial design experimental trials along with respectively obtained yield values
(%, w/w).
Experimental
Extent of apigenin incorporation,
X1 X2
trials
or Yield* (%, w/w)
1
0 +1
93.26 ± 0.82
2
0 0
90.28 ± 1.75
3
-1 -1
66.84 ± 1.39
4
+1 +1
89.70 ± 0.72
5
+1 -1
84.88 ± 1.47
6
-1 0
69.31 ± 1.63
7
+1 0
86.05 ± 1.21
8
0 -1
87.43 ± 1.32
9
-1 +1
74.66 ± 0.57
* Values represent mean ± Std. Dev. (n=3)

Table 3. Solubility analysis of pure apigenin, the physical mixture (1:1) of apigenin and
Phospholipon® 90H (PM), and apigenin- Phospholipon® 90H phytosome (APLC).
Sample Aqueous solubility (µg/mL)* n-octanol solubility (µg/mL)*
Apigenin
0.62 ± 0.88
603.02 ± 0.72
PM
6.13 ± 1.13
634.77 ± 1.25
APLC
22.80 ± 1.40
680.24 ± 1.21
*Data expressed as mean ± Std. Dev.; n = 3

Table 4. Influence of pure apigenin and APLC on rat liver function markers, Serum GlutamicPyruvic Transaminase (SGPT), Serum Glutamic-Oxaloacetic Transaminase (SGOT), Serum
Alkaline Phosphatase (SALP), and total bilirubin.

Treatment
Normal:
Tween® 20 (1%, v/v,
p.o.)
Control:
CCl4 + olive oil
(1:1, 5 mL/kg, i.p.)
Apigenin (25 mg/kg, p.o.)
+ [CCl4 + olive oil (1:1,
5 mL/kg, i.p., day 7)]
APLC (~25mg/kg
apigenin, p.o.)
+ [CCl4 + olive oil (1:1,
5 mL/kg, i.p., day 7)]
a

SGPT
(IU/L)a

SGOT
(IU/L)a

SALP
(IU/L)a

Total
bilirubin
(mg/dL)

36.86 ± 1.30**

38.31 ± 1.15**

134.90 ± 2.14**

0.35 ± 0.02**

76.94 ± 2.96

90.29 ± 3.47

182.20 ± 4.31

0.90 ± 0.05

63.02 ± 2.45

76.12 ± 1.40*

169.18 ± 2.90*

0.59 ± 0.03*

50.90 ± 1.63**

58.07 ± 1.51**

150.25 ± 2.40**

0.46 ± 0.01**

- IU/L – International Units/Liter of plasma

All values are Mean ± Std. Error of Mean (n = 6)

*p < 0.05, **p < 0.01 (significant with respect to control group)

Table 5. Estimated pharmacokinetic parameters after oral administration of pure apigenin (100
mg/kg, p.o.) or APLC (~100 mg/kg apigenin, p.o.).

Pharmacokinetic parameters
Cmax (µg ml-1)
Tmax (hours)
Area under concentration-time curve (AUC0 – t) (µg ml-1 h)
Area under concentration-time curve (AUC0–∞) (µg ml-1 h)
Elimination half-life (t1/2el) (h)
Elimination rate constant (Kel) (h-1)
Clearance (cl/F) [(mg)/(µgml-1h-1)
Volume of distribution (Vz/F) [(mg)/(µgml-1h-1)]
All values are Mean ± Std. Error of Mean (n = 6)

Treatment
Apigenin
APLC
(100 mg/kg,
(~100 mg/kg
p.o.)
apigenin, p.o.)
0.14 ± 0.15
0.20 ± 0.25
2.0 ± 0.23
4.0 ± 0.34
0.84 ± 0.42
1.31 ± 0.46
1.27 ± 0.28
1.95 ± 0.65
4.80 ± 0.33
4.34 ± 0.52
0.16 ± 0.04
0.14 ± 0.03
78.6 ± 0.45
51.18 ± 0.37
544.15 ± 0.31
320.72 ± 0.25

